NexImmune Announces Pricing of Upsized Initial Public Offering
11 févr. 2021 22h03 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to...
NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member
19 janv. 2021 08h30 HE
|
NexImmune, Inc.
Verstandig currently serves as Chief Digital Officer of UnitedHealth Group, where he is responsible for UnitedHealth Group’s digital platform and capabilities Founder of digital consumer healthcare...
Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer
18 janv. 2021 08h30 HE
|
NexImmune, Inc.
With more than 25 years of clinical development leadership experience at companies such as Celgene and Kite Pharmaceuticals, Dr. Knight will now lead the clinical development of NexImmune’s novel...
NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor
04 janv. 2021 06h00 HE
|
NexImmune, Inc.
Zeldis formerly served as Celgene CMO and CEO of Celgene Global HealthWeber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientistBoth will help NexImmune...
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition
07 déc. 2020 17h31 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Dec. 07, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to...
NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting
04 nov. 2020 14h00 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that an...
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia
27 oct. 2020 08h30 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it...
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
06 oct. 2020 08h30 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., Oct. 06, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing a portfolio of unique non-genetically-engineered T cell immunotherapies, announced...
NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)
23 sept. 2020 08h30 HE
|
NexImmune, Inc.
Company is using its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic malignancies GAITHERSBURG,...
NexImmune to Present at the Jefferies Virtual Healthcare Conference
01 juin 2020 09h37 HE
|
NexImmune, Inc.
GAITHERSBURG, Md., June 01, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharma company advancing a new generation of nanoparticle-based therapies for targeted immune system response,...